Cassava Sciences Files 8-K
Ticker: FLNA · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Sep 27, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $40 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, regulatory
TL;DR
Cassava Sciences filed an 8-K on 9/27 for events on 9/26. Details pending.
AI Summary
Cassava Sciences, Inc. filed an 8-K on September 27, 2024, reporting on events as of September 26, 2024. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates ongoing reporting requirements and potential disclosures for Cassava Sciences, Inc. Investors should review the full filing for any material updates.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification without specific material events or financial data, thus posing a low immediate risk.
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- 0001437749-24-030118 (filing_id) — Accession Number
- 20240927 (date) — Filing Date
- 20240926 (date) — Report Date
- Austin, Texas (location) — Principal Executive Offices
FAQ
What specific events are being disclosed under Regulation FD?
The provided excerpt does not detail the specific events being disclosed under Regulation FD.
Are there any new financial statements or exhibits attached to this filing?
The filing indicates 'Financial Statements and Exhibits' as an item, but the excerpt does not contain the actual statements or exhibits.
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was Cassava Sciences, Inc. incorporated and in which state?
Cassava Sciences, Inc. was incorporated in Delaware.
What is the business address and phone number for Cassava Sciences, Inc.?
The business address is 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731, and the phone number is (512) 501-2444.
Filing Stats: 829 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2024-09-27 07:36:59
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value SAVA Nasdaq Capital Market
- $40 million — reed to pay a civil monetary penalty of $40 million. As reported in its quarterly report on
Filing Documents
- sava20240927_8k.htm (8-K) — 29KB
- ex_727922.htm (EX-99.1) — 12KB
- lrglogo.jpg (GRAPHIC) — 9KB
- 0001437749-24-030118.txt ( ) — 193KB
- sava-20240926.xsd (EX-101.SCH) — 3KB
- sava-20240926_def.xml (EX-101.DEF) — 12KB
- sava-20240926_lab.xml (EX-101.LAB) — 15KB
- sava-20240926_pre.xml (EX-101.PRE) — 12KB
- sava20240927_8k_htm.xml (XML) — 3KB
01. Other Events
Item 7.01. Other Events. On September 26, 2024, Cassava Sciences, Inc. (the "Company" or "Cassava") issued a press release related to the matters described in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated into this Item 7.01 by reference. The information furnished in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events. On September 26, 2024, Cassava announced that it had reached a settlement with the U.S. Securities and Exchange Commission (the "SEC") resolving the previously reported SEC investigation of the Company's disclosures regarding its Phase 2b clinical trial of simufilam for the treatment of Alzheimer's disease (the "Phase 2b Study") and related matters. The SEC also agreed to a settlement with two former senior employees of the Company. The settlements with the Company and its former senior employees are subject to final approval by a U.S. District Court. The SEC's complaint alleges that certain disclosures by the Company regarding the Phase 2b Study violated certain federal securities laws and SEC rules, including negligence-based disclosure violations of Sections 17(a)(2) and 17(a)(3) of the Securities Act of 1933, as amended (the "Securities Act"), as well as recordkeeping and reporting requirements under the Exchange Act. The complaint alleges that the Company's SEC reports and other public statements regarding the Phase 2b Study negligently contained materially misleading statements and omissions. The SEC's allegations with respect to the Company's two former employees relate to these employees' roles in such disclosures. Under its settlement, the Company has consented to a permanent injunction against future violations of Section 17(a) of the Securities Act, Section 13(a)(1) of the Exchange Act and Rules 12b-20, 13a-1, 13a-11 and 13a-13 under the Exchange Act. In addition, Cassava has agreed to pay a civil monetary penalty of $40 million. As reported in its quarterly report on Form 10-Q for its second quarter of fiscal year 2024, the Company had reserved a loss contingency in that amount for the potential settlement of the SEC investigation. The Company also has implemented remedial measures and taken actions to enhance corporate governance. 9.01: Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release iss